Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to determine the safety and efficacy of a combination product for the prevention of veisalgia. Common symptoms of veisalgia following the moderate consumption of alcohol includes headache, fatigue, and thirst. It is the investigators hypothesis that a combination of two drugs can alleviate or significantly reduce these symptoms when taken before the start of moderate alcohol consumption.


Clinical Trial Description

Some people who consume alcohol in moderation experience veisalgia. These symptoms include a long list of adverse effects that include headache, fatigue and thirst. The mechanism by which these effects occur has not been fully elucidated. Although, it has been documented that alcohol causes the release of a large number of substances into the blood stream that cause a number of physiologic changes.

A 4-arm study will help to determine the effect each agent contributes to decreasing the alcohol induces physiologic changes and the effect when the two agents are delivered concurrently. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02737397
Study type Interventional
Source JMI Capital Group
Contact
Status Completed
Phase Phase 2
Start date March 2016
Completion date May 2016

See also
  Status Clinical Trial Phase
Not yet recruiting NCT03183297 - Study to Evaluate the Pharmacokinetics and Pharmacodynamics of JMI-001 Phase 1